Frontiers in Oncology (Dec 2020)

Durable Response to Sintilimab and Chidamide in a Patient With Pegaspargase- and Immunotherapy-Resistant NK/T-Cell Lymphoma: Case Report and Literature Review

  • Zheng Yan,
  • Shuna Yao,
  • Yanyan Liu,
  • Jianbo Zhang,
  • Peng Li,
  • Haiying Wang,
  • Junfeng Chu,
  • Shuang Zhao,
  • Zhihua Yao

DOI
https://doi.org/10.3389/fonc.2020.608304
Journal volume & issue
Vol. 10

Abstract

Read online

The prognosis of patients with relapsed/refractory NK/T-cell lymphoma (NKTCL) is dismal. Immunotherapy has showed encouraging anti-tumor activity in patients with asparaginase-resistant NKTCL; however, only a portion of patients benefit and the median response duration is rather short. Treatment strategies have not been identified for immunotherapy-resistant NKTCL. We describe a patient with primary cutaneous NKTCL experienced disease progression after pegaspargase-based chemotherapy and PD-1 inhibitor (sintilimab)-based immunotherapy. Following a combined treatment of sintilimab and the HDAC inhibitor chidamide, the patient achieved a durable complete molecular response with mild toxicity. This case indicates that the combination of PD-1 inhibitor and HDAC inhibitor might be a treatment choice for immunotherapy-resistant NKTCL.

Keywords